30 years of research based on hydroxyapatite
for the future of health
Hastim is a human-sized, agile and innovative company. Its objective is to develop an immunotherapeutic treatment for humans. In a "One Health" approach, in parallel to its research in human health, it has launched a treatment for veterinary cancer.
Health: A common good of the human, animal and environmental world
A unique technology
Years of research have demonstrated the effectiveness of hydroxyapatite associated with tumour cell proteins in the fight against cancer
To propose a personalised treatment of cancer with low environmental impact
Soon available to veterinarians prescribing APAVAC immunotherapy, an online application for collecting clinical cases to record, track and compare in “real time” the results of the treatment among the user pool.